Glucocorticoid-induced osteoporosis

Curr Rheumatol Rep. 2000 Feb;2(1):53-61. doi: 10.1007/s11926-996-0069-4.

Abstract

This article attempts to evaluate the results of several recently published clinical trials of drugs used in the treatment and prevention of glucocorticoid-induced osteoporosis. Despite our lack of understanding regarding the biological mechanisms that lead to glucocorticoid-induced bone loss, effective therapy has been developed. Bisphosphonates have demonstrated significant treatment benefits and should be considered the therapy of choice for both the treatment and prevention of glucocorticoid-induced osteoporosis.

Publication types

  • Review

MeSH terms

  • Calcitonin / administration & dosage
  • Calcium Compounds / administration & dosage
  • Diphosphonates / administration & dosage
  • Female
  • Fluorides / administration & dosage
  • Glucocorticoids / adverse effects*
  • Glucocorticoids / therapeutic use
  • Humans
  • Male
  • Osteoporosis / chemically induced*
  • Osteoporosis / drug therapy*
  • Osteoporosis / prevention & control
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Vitamin D / administration & dosage

Substances

  • Calcium Compounds
  • Diphosphonates
  • Glucocorticoids
  • Vitamin D
  • Calcitonin
  • Fluorides